NCT01467882 - Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

July 31, 2014

Conditions

Central Precocious Puberty

Interventions

DRUG

Triptorelin

Powder and solution for solution for injection

Trial Locations (13)

Nancy Wright MD P.A., Tallahassee

Lynn health Science Institute, Oklahoma City

Pediatric Endocrinology of Phoenix, Phoenix

Children's National Medical Center, San Diego

Children's National Medical Center, Washington D.C.

Arnold Palmer Pediatric Endocrinology Practice, Orlando

Washington University, St Louis

Hackensack university medical center, Hackensack

Women's & Children's Hospital of Buffalo, Buffalo

Cincinnati Children's Hospital, Cincinnati

Swedish Pediatric Specialist, Seattle

IDIMI, Santiago

Hospital Universitario de Monterrey, Monterrey